Seelhammer Troy G, DeGraff Eric M, Behrens Travis J, Robinson Justin C, Selleck Kristen L, Schroeder Darrell R, Sprung Juraj, Weingarten Toby N
Mayo Clinic, Department of Anesthesiology and Perioperative Medicine, Rochester, Estados Unidos.
Mayo Clinic College of Medicine, Mayo School of Health Sciences, Rochester, Estados Unidos.
Braz J Anesthesiol. 2018 Jul-Aug;68(4):329-335. doi: 10.1016/j.bjan.2017.12.012. Epub 2018 Apr 7.
The primary aim was to determine risk factors for flumazenil administration during postanesthesia recovery. A secondary aim was to describe outcomes among patients who received flumazenil.
Patients admitted to the postanesthesia recovery room at a large, academic, tertiary care facility after surgery under general anesthesia from January 1, 2010, to April 30, 2015, were identified and matched to 2 controls each, by age, sex, and surgical procedure. Flumazenil was administered in the recovery phase immediately after general anesthesia, according to the clinical judgment of the anesthesiologist. Demographic, procedural, and outcome data were extracted from the electronic health record. Conditional logistic regression, accounting for the 1:2 matched-set case-control study designs, was used to assess characteristics associated with flumazenil use.
The incidence of flumazenil administration in the postanesthesia care unit was 9.9 per 10,000 (95% CI, 8.4–11.6) general anesthetics. History of obstructive sleep apnea (Odds Ratio [OR] = 2.27; 95% CI 1.02–5.09), longer anesthesia (OR = 1.13; 95% CI 1.03–1.24 per 30 minutes), use of total intravenous anesthesia (OR = 6.09; 95% CI 2.60–14.25), and use of benzodiazepines (OR = 8.17; 95% CI 3.71–17.99) were associated with risk for flumazenil administration. Among patients who received midazolam, cases treated with flumazenil received a higher median (interquartile range) dose than controls: 3.5 mg (2.0–4.0 mg) vs. 2.0 mg (2.0–2.0 mg), respectively ( < 0.001). Flumazenil use was correlated with a higher rate of unanticipated noninvasive positive pressure ventilation, longer postanesthesia care unit stay, and increased rate of intensive care unit admissions.
Patients who required flumazenil postoperatively had received a higher dosage of benzodiazepines and utilized more postoperative health care resources. More conservative perioperative use of benzodiazepines may improve postoperative recovery and use of health care resources.
主要目的是确定麻醉后恢复期间使用氟马西尼的危险因素。次要目的是描述接受氟马西尼治疗患者的结局。
确定2010年1月1日至2015年4月30日在一家大型学术三级医疗中心接受全身麻醉手术后入住麻醉后恢复室的患者,并根据年龄、性别和手术程序为每位患者匹配2名对照。根据麻醉医生的临床判断,在全身麻醉后立即在恢复阶段给予氟马西尼。从电子健康记录中提取人口统计学、手术和结局数据。采用考虑1:2匹配病例对照研究设计的条件逻辑回归分析来评估与氟马西尼使用相关的特征。
麻醉后护理单元中氟马西尼的给药发生率为每10,000例全身麻醉中9.9例(95%置信区间,8.4 - 11.6)。阻塞性睡眠呼吸暂停病史(优势比[OR]=2.27;95%置信区间1.02 - 5.09)、麻醉时间延长(OR=1.13;每30分钟95%置信区间1.03 - 1.24)、使用全静脉麻醉(OR=6.09;95%置信区间2.60 - 14.25)以及使用苯二氮䓬类药物(OR=8.17;95%置信区间3.71 - 17.99)与氟马西尼给药风险相关。在接受咪达唑仑的患者中,接受氟马西尼治疗的病例的中位(四分位间距)剂量高于对照组:分别为3.5mg(2.0 - 4.0mg)和2.0mg(2.0 - 2.0mg)(<0.001)。使用氟马西尼与意外无创正压通气率较高、麻醉后护理单元停留时间延长以及重症监护病房入住率增加相关。
术后需要氟马西尼的患者接受了更高剂量的苯二氮䓬类药物,并且使用了更多的术后医疗资源。围手术期更保守地使用苯二氮䓬类药物可能会改善术后恢复并减少医疗资源的使用。